ATE401088T1 - Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs - Google Patents

Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs

Info

Publication number: ATE401088T1
Authority: AT; Austria
Prior art keywords: cancer; antisense oligonucleotide; gemcitabine; treatment; composition
Prior art date: 2004-04-22

Application number

AT05738307T

Other languages

English (en)

Inventor

Bharvin Patel

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-22

Filing date

2005-04-15

Publication date

2008-08-15

2005-04-15 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE401088T1 publication Critical patent/ATE401088T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
108091034117 Oligonucleotide Proteins 0.000 title abstract 2
102000000763 Survivin Human genes 0.000 title abstract 2
108010002687 Survivin Proteins 0.000 title abstract 2
239000000074 antisense oligonucleotide Substances 0.000 title abstract 2
238000012230 antisense oligonucleotides Methods 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
229960005277 gemcitabine Drugs 0.000 title 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT05738307T 2004-04-22 2005-04-15 Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs ATE401088T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US56454004P	2004-04-22	2004-04-22

Publications (1)

Publication Number	Publication Date
ATE401088T1 true ATE401088T1 (de)	2008-08-15

Family

ID=35094133

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT07119706T ATE538800T1 (de)	2004-04-22	2005-04-15	Kombinationstherapie zur krebsbehandlung
AT05738307T ATE401088T1 (de)	2004-04-22	2005-04-15	Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT07119706T ATE538800T1 (de)	2004-04-22	2005-04-15	Kombinationstherapie zur krebsbehandlung

Country Status (17)

Country	Link
US (3)	US20070244065A1 (de)
EP (3)	EP2145626A1 (de)
JP (1)	JP2007533742A (de)
CN (2)	CN101683355A (de)
AT (2)	ATE538800T1 (de)
AU (1)	AU2005240020B2 (de)
BR (1)	BRPI0509927A (de)
CA (1)	CA2562750A1 (de)
CY (2)	CY1110440T1 (de)
DE (1)	DE602005008241D1 (de)
DK (2)	DK1913947T3 (de)
ES (2)	ES2376484T3 (de)
MX (1)	MXPA06012132A (de)
PL (2)	PL1913947T3 (de)
PT (2)	PT1763356E (de)
SI (2)	SI1913947T1 (de)
WO (1)	WO2005107771A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2310006A4 (de)	2008-07-03	2012-04-25	Mayo Foundation	Krebsbehandlung
FR2955112B1 (fr)	2010-01-14	2012-01-20	Isp Investments Inc	Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant
WO2012058462A2 (en) *	2010-10-29	2012-05-03	Isis Pharmaceuticals, Inc.	Combination therapy for the treatment of cancer
EP2707030B1 (de)	2011-05-09	2020-02-19	Mayo Foundation For Medical Education And Research	Krebsbehandlungen
EP3967306A1 (de)	2012-10-01	2022-03-16	Mayo Foundation for Medical Education and Research	Krebsbehandlungen
US20160250351A1 (en)	2014-06-13	2016-09-01	Mayo Foundation For Medical Education And Research	Treating Lymphomas
KR20210125603A (ko)	2014-06-16	2021-10-18	메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치	골수종의 치료
US9446148B2 (en)	2014-10-06	2016-09-20	Mayo Foundation For Medical Education And Research	Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh)	2015-08-18	2017-03-01	美國馬友醫藥教育研究基金會	載體－抗體組合物及其製造及使用方法
TW201713360A (en)	2015-10-06	2017-04-16	Mayo Foundation	Methods of treating cancer using compositions of antibodies and carrier proteins
US11571469B2 (en)	2016-01-07	2023-02-07	Mayo Foundation For Medical Education And Research	Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
EP3413874A4 (de)	2016-02-12	2020-01-22	Mayo Foundation for Medical Education and Research	Behandlungen für blutkrebs
AU2017238119A1 (en)	2016-03-21	2018-10-11	Mayo Foundation For Medical Education And Research	Methods for reducing toxicity of a chemotherapeutic drug
WO2017165439A1 (en)	2016-03-21	2017-09-28	Mayo Foundation For Medical Education And Research	Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en)	2016-04-06	2020-04-14	Mayo Foundation For Medical Education And Research	Carrier-binding agent compositions and methods of making and using the same
WO2018045238A1 (en)	2016-09-01	2018-03-08	Mayo Foundation For Medical Education And Research	Methods and compositions for targeting t-cell cancers
ES2937291T3 (es)	2016-09-01	2023-03-27	Mayo Found Medical Education & Res	Composiciones de agentes que se unen al transportador PD-L1 y métodos de uso de las mismas para tratar cánceres
CN109890422A (zh)	2016-09-06	2019-06-14	梅约医学教育与研究基金会	紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
US11590098B2 (en)	2016-09-06	2023-02-28	Mayo Foundation For Medical Education And Research	Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CN109843924A (zh)	2016-09-06	2019-06-04	梅约医学教育与研究基金会	治疗表达pd-l1的癌症的方法
IL291917A (en) *	2019-10-02	2022-06-01	Sirnaomics Inc	Oligonucleotides with nucleoside analogs, compositions comprising same and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0184365B1 (de) *	1984-12-04	1993-08-04	Eli Lilly And Company	Tumorbehandlung bei Säugetieren
US6077709A (en) *	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6335194B1 (en) *	1998-09-29	2002-01-01	Isis Pharmaceuticals, Inc.	Antisense modulation of survivin expression
US6838283B2 (en) *	1998-09-29	2005-01-04	Isis Pharmaceuticals Inc.	Antisense modulation of survivin expression
MXPA05008319A (es) *	2003-02-10	2006-02-28	Santaris Pharma As	Compuestos oligomericos para la modulacion de la expresion de survivina.

2005
- 2005-04-15 CN CN200910163328A patent/CN101683355A/zh active Pending
- 2005-04-15 US US11/587,219 patent/US20070244065A1/en not_active Abandoned
- 2005-04-15 DK DK07119706.5T patent/DK1913947T3/da active
- 2005-04-15 WO PCT/US2005/012968 patent/WO2005107771A2/en not_active Ceased
- 2005-04-15 PT PT05738307T patent/PT1763356E/pt unknown
- 2005-04-15 DK DK05738307T patent/DK1763356T3/da active
- 2005-04-15 AT AT07119706T patent/ATE538800T1/de active
- 2005-04-15 JP JP2007509532A patent/JP2007533742A/ja active Pending
- 2005-04-15 BR BRPI0509927-7A patent/BRPI0509927A/pt not_active IP Right Cessation
- 2005-04-15 SI SI200531449T patent/SI1913947T1/sl unknown
- 2005-04-15 PT PT07119706T patent/PT1913947E/pt unknown
- 2005-04-15 EP EP09168514A patent/EP2145626A1/de not_active Withdrawn
- 2005-04-15 AT AT05738307T patent/ATE401088T1/de active
- 2005-04-15 EP EP07119706A patent/EP1913947B1/de not_active Expired - Lifetime
- 2005-04-15 PL PL07119706T patent/PL1913947T3/pl unknown
- 2005-04-15 CA CA002562750A patent/CA2562750A1/en not_active Abandoned
- 2005-04-15 AU AU2005240020A patent/AU2005240020B2/en not_active Ceased
- 2005-04-15 CN CNA2005800118267A patent/CN1950094A/zh active Pending
- 2005-04-15 ES ES07119706T patent/ES2376484T3/es not_active Expired - Lifetime
- 2005-04-15 ES ES05738307T patent/ES2308488T3/es not_active Expired - Lifetime
- 2005-04-15 EP EP05738307A patent/EP1763356B1/de not_active Expired - Lifetime
- 2005-04-15 SI SI200530382T patent/SI1763356T1/sl unknown
- 2005-04-15 DE DE602005008241T patent/DE602005008241D1/de not_active Expired - Lifetime
- 2005-04-15 PL PL05738307T patent/PL1763356T3/pl unknown
- 2005-04-15 MX MXPA06012132A patent/MXPA06012132A/es active IP Right Grant
2008
- 2008-09-24 CY CY20081101036T patent/CY1110440T1/el unknown
2009
- 2009-03-13 US US12/403,561 patent/US20090247611A1/en not_active Abandoned
2011
- 2011-09-28 US US13/246,890 patent/US20120022140A1/en not_active Abandoned
2012
- 2012-02-24 CY CY20121100197T patent/CY1112397T1/el unknown

Also Published As

Publication number	Publication date
ES2308488T3 (es)	2008-12-01
US20090247611A1 (en)	2009-10-01
PL1763356T3 (pl)	2008-12-31
EP1763356B1 (de)	2008-07-16
EP1913947A1 (de)	2008-04-23
CN1950094A (zh)	2007-04-18
AU2005240020A1 (en)	2005-11-17
SI1913947T1 (sl)	2012-02-29
BRPI0509927A (pt)	2007-09-25
DK1763356T3 (da)	2008-10-13
DK1913947T3 (da)	2012-02-06
SI1763356T1 (sl)	2008-12-31
EP2145626A1 (de)	2010-01-20
DE602005008241D1 (de)	2008-08-28
ATE538800T1 (de)	2012-01-15
WO2005107771A2 (en)	2005-11-17
CA2562750A1 (en)	2005-11-17
US20070244065A1 (en)	2007-10-18
ES2376484T3 (es)	2012-03-14
JP2007533742A (ja)	2007-11-22
CY1110440T1 (el)	2015-04-29
PL1913947T3 (pl)	2012-05-31
EP1913947B1 (de)	2011-12-28
EP1763356A2 (de)	2007-03-21
CN101683355A (zh)	2010-03-31
PT1913947E (pt)	2012-01-19
US20120022140A1 (en)	2012-01-26
PT1763356E (pt)	2008-09-05
WO2005107771A3 (en)	2006-06-08
AU2005240020B2 (en)	2011-02-10
CY1112397T1 (el)	2015-12-09
MXPA06012132A (es)	2007-01-17

Legal Events

Date

Code

Title

Description

2009-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1763356

Country of ref document: EP

Publication	Publication Date	Title
ATE401088T1 (de)	2008-08-15	Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs
ATE345130T1 (de)	2006-12-15	Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
DE602006017965D1 (de)	2010-12-16	Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
EP1622608A4 (de)	2010-11-10	Zusammensetzungen und verfahren zur behandlung von krebs
PH12012502380B1 (en)	2019-08-23	Methods of treatment of pancreatic cancer
BRPI0511139B8 (pt)	2021-05-25	compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
MX2009006466A (es)	2009-06-26	Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
CY1111263T1 (el)	2015-08-05	Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
BRPI0906181A2 (pt)	2015-06-30	"método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
MX383644B (es)	2025-03-14	Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
UA107783C2 (en)	2015-02-25	Isoindoline compounds for use in treating cancer
ATE525070T1 (de)	2011-10-15	Silbininkomponente zur behandlung von hepatitis
EA201001749A1 (ru)	2011-06-30	Способ лечения недифференцированного артрита
ATE459353T1 (de)	2010-03-15	Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
EP4138843A4 (de)	2024-07-10	Zusammensetzung zur behandlung von blutkrebs mit 4'-thio-5-aza-2'-deoxycytidin und verwendungen davon
EA201200428A1 (ru)	2013-02-28	Композиция и способ для лечения ожирения
ATE522531T1 (de)	2011-09-15	Indolylpyrrolidine zur behandlung von krebs
DE602005020113D1 (de)	2010-05-06	Verfahren zur behandlung von akuten rhinosinusitis
ATE473277T1 (de)	2010-07-15	Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
ATE477820T1 (de)	2010-09-15	Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
ATE510530T1 (de)	2011-06-15	Verfahren zur verhinderung und/oder behandlung von altersflecken
DE60334289D1 (de)	2010-11-04	Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE537838T1 (de)	2012-01-15	Kombinationstherapie mit kloretazin(tm)
HK1183815A (en)	2014-01-10	Methods of treatment of pancreatic cancer
UA110795C2 (uk)	2016-02-25	Спосіб лікування раку підшлункової залози